These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36873896)

  • 1. Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases.
    Stanel SC; Rivera-Ortega P
    Front Med (Lausanne); 2023; 10():1114722. PubMed ID: 36873896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.
    Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P
    Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
    Shumar JN; Chandel A; King CS
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 11. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD).
    Copeland CR; Lancaster LH
    Front Med (Lausanne); 2021; 8():743977. PubMed ID: 34722582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C; Cottin V
    Curr Opin Pulm Med; 2022 Sep; 28(5):407-413. PubMed ID: 35938201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be.
    Goos T; De Sadeleer LJ; Yserbyt J; Verleden GM; Vermant M; Verleden SE; Wuyts WA
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
    Nagy A; Nagy T; Kolonics-Farkas AM; Eszes N; Vincze K; Barczi E; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Bohacs A; Müller V
    Front Pharmacol; 2021; 12():778649. PubMed ID: 35002713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
    Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
    Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
    Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life prevalence of progressive fibrosing interstitial lung diseases.
    Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
    Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases.
    Torres PPTES; Rabahi MF; Moreira MADC; Escuissato DL; Meirelles GSP; Marchiori E
    J Bras Pneumol; 2021; 47(3):e20200096. PubMed ID: 34076172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.